JP Patent

JP6666490B2 — Ｃｇｒｐ活性化合物の錠剤製剤

Assigned to Merck Sharp and Dohme LLC · Expires 2020-03-13 · 6y expired

What this patent protects

Patent listed against Ubrelvy.

Drugs covered by this patent

Patent Metadata

Patent number
JP6666490B2
Jurisdiction
JP
Classification
—
Expires
2020-03-13
Drug substance claim
No
Drug product claim
No
Assignee
Merck Sharp and Dohme LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.